This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
ARHGEF2 / Rho guanine nucleotide exchange factor 2 · IHC design guide
Design Immunohistochemistry for ARHGEF2
Plan chromogenic ARHGEF2 IHC in paraffin sections using the IHC-validated antibody (datasheet A02572-3). Compare cytoplasmic staining in bone marrow hematopoietic cells and lymph node germinal center cells with adipocytes, where staining was not detected (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
ARHGEF2 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Variable cytoplasmic staining in tissues (HPA tissue IHC) | |
| Staining pattern | Cytoplasmic signal in hematopoietic and germinal center cells (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A02572-3) | |
| Positive control | Bone marrow+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation conditions consistent across sections. (standard IHC practice; not target-specific) | |
| Caveat | Staining has medium agreement with RNA expression (HPA tissue IHC) | |
| Regulation | Stimulus-dependent expression is unreported (UniProt) | |
| Isoform / epitope | 3 isoforms; epitope coverage is unknown (UniProt) |
Section 1
Recommended ARHGEF2 IHC & IF Protocols
Compare the catalog antibody’s IHC protocol with one published ARHGEF2 tissue staining protocol (PMC9637107: IHC methods).
| Sample | Paraffin-embedded human colon cancer tissue; fixative not specified (datasheet A02572-3) |
| Fixation | Image fixative and duration unreported (datasheet A02572-3); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A02572-3); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A02572-3) |
| Primary antibody | Rabbit anti-ARHGEF2, 2-5 μg/ml (datasheet A02572-3) |
| Primary incubation | Overnight at 4 °C (datasheet A02572-3) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet A02572-3) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | ARHGEF2-positive staining in hematopoietic cells of bone marrow (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic expression of varying intensities in several different tissue types. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA retrieval at pH 8.0 for the catalog antibody (datasheet: A02572-3); the published protocol used Tris-EDTA at pH 9.0 (PMC9637107: IHC methods).
Section 2
What Is the Expected ARHGEF2 Staining Pattern?
ARHGEF2 is mainly cytoplasmic and cytoskeleton associated, with reported localization at tight junctions, spindle tips, ruffles and vesicles (UniProt Q92974 subcellular location). In paraffin tissue sections, expect staining of hematopoietic cells in bone marrow, germinal center cells in lymph node or tonsil, and late spermatids in testis (HPA: High). HPA rates its tissue IHC profile Approved, with medium consistency between staining and RNA data and external verification pending (HPA tissue IHC).
| Cytoplasmic staining in bone marrow hematopoietic cells or germinal center cells, with nearby cells staining less strongly. | This fits the reported compartment and high staining in those cell populations (UniProt Q92974 subcellular location; HPA: High in bone marrow, lymph node and tonsil). Judge the named cells rather than requiring uniform staining across the section (HPA: varying cytoplasmic intensities). |
| A predominantly nuclear stain, with little convincing cytoplasmic signal. | A nuclear-only pattern conflicts with the reported cytoplasmic and cytoskeleton-associated locations (UniProt Q92974 subcellular location). Check morphology, counterstain and a negative reagent control before interpreting it as ARHGEF2; an unusual pattern alone does not identify the artefact (general IHC practice). |
| Strong staining of adipocytes or cardiomyocytes while expected positive cells remain unstained. | HPA reports ARHGEF2 as not detected in adipocytes and cardiomyocytes (HPA tissue IHC). Consider antibody cross-reactivity or endogenous chromogen activity, then compare with a reagent control and an HPA high-staining cell population (general IHC practice; HPA: High in bone marrow hematopoietic cells). |
| Brown deposit spread across tissue, lumens or section edges without a clear cell-specific pattern. | That distribution does not match the reported cytoplasmic staining in defined cells (HPA tissue IHC). Inspect background and reagent controls; nonspecific binding, endogenous detection activity or deposited chromogen are possible workflow causes (general IHC practice). |
| No visible staining in bone marrow hematopoietic cells, lymph node germinal centers or late spermatids. | These are HPA high-staining populations, so a blank result warrants a technical check (HPA tissue IHC). Confirm that the relevant cells are present, then review the IHC-validated antibody and detection controls; HPA's Approved rating still has external verification pending (HPA antibody validation; HPA tissue IHC; general IHC practice). |
💡Expected ARHGEF2 appearanceCall a result positive when cytoplasmic signal is clear in HPA high-staining hematopoietic cells, germinal center cells or late spermatids, allowing variable intensity across tissues; predominantly nuclear or indiscriminate section-wide staining is suspect (UniProt Q92974 subcellular location; HPA tissue IHC).
| Compartment and topology | ARHGEF2 is reported in cytoplasm and cytoskeleton, with additional junctional, spindle, ruffle, Golgi and vesicle locations; it has no transmembrane segment (UniProt Q92974 subcellular location; UniProt Q92974 topology). Focal peripheral signal may fit that annotation, but a solely nuclear result needs review (UniProt Q92974 subcellular location). |
| Choice of comparison cells | HPA reports High staining in bone marrow hematopoietic cells, lymph node and tonsil germinal center cells, and late spermatids; adipocytes and cardiomyocytes are Not detected (HPA tissue IHC). Compare the specified cell populations within well-preserved sections rather than treating an entire tissue as uniformly positive or negative (HPA tissue IHC; general IHC practice). |
| Strength of validation | The tissue profile is Approved, with medium staining-to-RNA consistency and external verification pending; HPA043437 is listed as IHC Approved (HPA tissue IHC; HPA antibody validation). These labels support a reference pattern but do not establish identical staining for every antibody or specimen (HPA tissue IHC; general IHC practice). |
| IF/ICC Q: Is a reference fluorescence pattern available? | A: HPA provides no main subcellular location and lists no cell lines with ICC-IF images in this payload (HPA subcellular ICC-IF). UniProt reports cytoplasmic and cytoskeleton-associated locations, but the HPA tissue IHC pattern should not be treated as an independently verified IF image pattern (UniProt Q92974 subcellular location; HPA subcellular ICC-IF). |
| Situation | Likely cause | Next action |
|---|---|---|
| Expected positive cells are blank, including a high-staining comparison population (HPA tissue IHC). | The relevant cells may be absent from the section, or the IHC staining run may have failed; the slide alone cannot distinguish these causes (general IHC practice). | Verify cell identity on the counterstained section and check a concurrently processed positive control, antibody application and detection reagents (general IHC practice). |
| Signal is weak in a population HPA rates High (HPA tissue IHC). | Target-specific fixation effects are not established by the supplied assay evidence. Verify with a matched IHC source before attributing a result to fixation. | Compare with an HPA high-staining control and review the validated IHC-P workflow, including retrieval and detection steps, as general IHC checks (HPA tissue IHC; general IHC practice). |
| Diffuse brown background obscures cells (general IHC practice). | Nonspecific reagent binding or endogenous detection activity can produce background in chromogenic IHC (general IHC practice). | Inspect a negative reagent control, blocking and wash steps, and the detection system; score ARHGEF2 only where a distinct cellular pattern remains (general IHC practice; UniProt Q92974 subcellular location). |
| Adipocytes or cardiomyocytes appear strongly positive (HPA: Not detected in those cells). | Cross-reactivity or endogenous detection activity is possible; HPA's reference pattern alone cannot determine which applies (HPA tissue IHC; general IHC practice). | Compare those cells with an HPA high-staining population and examine negative reagent controls before assigning the stain to ARHGEF2 (HPA tissue IHC; general IHC practice). |
| Staining appears mainly nuclear rather than cytoplasmic (UniProt Q92974 subcellular location). | The pattern is discordant with the supplied location annotation; counterstain overlap or nonspecific staining may complicate interpretation (UniProt Q92974 subcellular location; general IHC practice). | Review nuclear boundaries at higher magnification and compare the antibody-stained section with a negative reagent control and an HPA high-staining cell population (general IHC practice; HPA tissue IHC). |
| An IF/ICC image seems inconsistent with the tissue IHC result (HPA tissue IHC; HPA subcellular ICC-IF). | The supplied HPA ICC-IF record has no image-bearing cell lines or main location, so it offers no independent fluorescence pattern for comparison (HPA subcellular ICC-IF). | Interpret this page's positive call from tissue IHC and UniProt localization; assess any IF/ICC experiment using its own controls and guide (HPA tissue IHC; UniProt Q92974 subcellular location; general IF practice). |
Experiment evidence
IHC & IF images showing ARHGEF2 staining
A02572-3 · IHCIHC analysis of GEF-H1/ARHGEF2 using anti-GEF-H1/ARHGEF2 antibody (A02572-3). GEF-H1/ARHGEF2 was detected in a paraffin-embedded section of
A02572-3 · IHCIHC analysis of GEF-H1/ARHGEF2 using anti-GEF-H1/ARHGEF2 antibody (A02572-3). GEF-H1/ARHGEF2 was detected in a paraffin-embedded section of
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000116584-ARHGEF2/tissue/cerebral+cortex#imid_20123245
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000116584-ARHGEF2/tissue/colon#imid_20123171
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000116584-ARHGEF2/tissue/liver#imid_20123180
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000116584-ARHGEF2/tissue/kidney#imid_20123173
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for ARHGEF2 IHC & IF
🧪Run bone marrow first; hematopoietic cells should stain (HPA: High in bone marrow hematopoietic cells). Use adipose tissue as the negative tissue, with adipocytes expected to remain unstained (HPA: Not detected in adipocytes); on the marrow slide, cells lacking specific signal should show only background, but HPA does not identify a specific negative marrow cell type.
Positive control tissue: Bone marrow (Hematopoietic cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA carries no ICC-IF cell line for ARHGEF2; derive a cell-line control from the positive tissue's cell type (Hematopoietic cells) and confirm it by RNA or western blot first.
Technical controls: Include a no-primary, secondary-only control and a control immunoglobulin matched to the primary antibody’s rabbit host and clonality (caption: rabbit primary antibody; standard IHC practice). Use an ARHGEF2 knockout specimen processed in parallel as a biological negative, and quench endogenous peroxidase in bone marrow before HRP/DAB detection (standard IHC practice; caption: HRP/DAB detection).
⚠️Feasibility: No target-specific fixation window or fixation effect is reported in the supplied evidence, and the selected A02572-3 paraffin-section caption does not state the fixative (caption: fixative unreported). The reported IHC example uses heat retrieval in EDTA at pH 8.0, but it does not establish whether retrieval is required; the evidence also does not establish whether frozen sections or IF are easier (caption: EDTA retrieval in a paraffin section). Bone marrow can produce endogenous peroxidase background with chromogenic detection, so interpret staining against the quenched controls (standard IHC practice; caption: HRP/DAB detection).
HPA tissue IHC evidence for ARHGEF2
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Medium consistency between antibody staining and RNA expression data. Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Bone marrow | Hematopoietic cells | High | Protein (IHC) | HPA → |
| Lymph node | Germinal center cells | High | Protein (IHC) | HPA → |
| Testis | Elongated or late spermatids | High | Protein (IHC) | HPA → |
| Tonsil | Germinal center cells | High | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Bronchus | Basal cells | Not detected | Protein (IHC) | HPA → |
| Cervix | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Epididymis | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Esophagus | Squamous epithelial cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced ARHGEF2 IHC Tips
Troubleshoot ARHGEF2 staining in paraffin sections by checking retrieval, cellular pattern, controls, and scoring before interpreting changes in signal.
How should I retrieve ARHGEF2 in paraffin sections when staining is weak?
Start with heat-mediated retrieval in EDTA at pH 8.0 (datasheet A02572-3). The demonstrated paraffin-section workflow then used 2 μg/ml catalog antibody overnight at 4°C, so keep that incubation constant while assessing retrieval (datasheet A02572-3). If staining remains weak, compare a modestly longer heat step with the original condition on adjacent sections, recording temperature and heating time for each run (standard IHC practice). Include a known positive compartment, such as bone marrow hematopoietic cells, and inspect morphology before accepting stronger staining as improved detection (HPA: High in bone marrow hematopoietic cells; standard IHC practice).
Could fixation explain variable ARHGEF2 staining between paraffin blocks?
Target-specific fixation sensitivity is unknown: the selected paraffin-section caption does not report its fixative (datasheet A02572-3). Record the fixative, fixation duration, tissue thickness, and processing history for each block; compare sections processed together before attributing a difference to ARHGEF2 biology (standard IHC practice). If preparing new material, use a consistent routine fixation schedule and test, for example, 6 versus 24 hours as a controlled pilot rather than assuming either duration preserves this epitope (standard IHC practice). Apply the same EDTA retrieval at pH 8.0 to both conditions, and judge signal alongside tissue morphology and a positive control (datasheet A02572-3; standard IHC practice).
Which staining compartments fit ARHGEF2, and when should I question the pattern?
Expect predominantly cytoplasmic staining across tissue types, with context-dependent association with cytoskeleton, tight junctions, Golgi, spindle, ruffles, or cytoplasmic vesicles (HPA: cytoplasmic tissue expression; UniProt Q92974 subcellular). ARHGEF2 has no transmembrane segment, so a continuous membrane-only rim warrants validation rather than automatic acceptance (UniProt Q92974 topology; standard IHC practice). Compare the chromogenic signal with cell outlines and a counterstain on the same section, especially where densely packed cells could make cytoplasm look nuclear (standard IHC practice). A focal spindle or junctional pattern can be plausible in the appropriate cellular context, but require reproducibility and clean negative controls before assigning it biological meaning (UniProt Q92974 subcellular; standard IHC practice).
How can isoforms or epitope accessibility affect this antibody’s IHC pattern?
ARHGEF2 has 3 annotated isoforms, while the supplied caption does not identify the antibody epitope or establish isoform coverage (UniProt Q92974 isoforms; datasheet A02572-3). Its DH domain spans residues 235–432 and PH domain spans 472–571; multiple modified residues are also reported, but their effect on this antibody is unknown (UniProt Q92974 domains and modified residues). Obtain the immunogen or epitope map before claiming that loss of tissue staining reflects a particular isoform (standard IHC practice). Keep retrieval and antibody concentration fixed when comparing specimens, then confirm any proposed isoform-specific interpretation with an independent assay that distinguishes the relevant transcripts or proteins (standard IHC practice).
How should I adapt this IHC finding to multiplex IF without overinterpreting fluorescence?
Treat multiplex IF as a separate validation: the supplied product example documents chromogenic staining in paraffin-embedded human colon cancer tissue, without reporting an IF result or fixative (datasheet A02572-3). Pair ARHGEF2 with a validated CD45 marker when examining the hematopoietic cells reported as strongly stained in bone marrow, and check each channel separately before interpreting overlap (HPA: High in bone marrow hematopoietic cells; standard IF practice). Choose spectrally separated fluorophores after measuring tissue autofluorescence, favoring a brighter, longer-wavelength channel for a weak target signal (standard IF practice). Because ARHGEF2 lacks a transmembrane segment and is chiefly cytoplasmic, test gentle permeabilisation for intracellular epitope access while preserving cell structure (UniProt Q92974 topology and subcellular; standard IF practice).
What should I adjust when ARHGEF2 DAB staining appears diffuse or nonspecific?
First compare the stained section with a no-primary control and inspect whether diffuse color follows tissue folds, damaged edges, or pigment rather than cells (standard IHC practice). The demonstrated workflow used 10% goat serum, 2 μg/ml primary antibody overnight at 4°C, and an enzyme-linked secondary for 30 minutes at 37°C (datasheet A02572-3). If background is high, titrate the primary below that starting concentration, optimize washes, and include a peroxidase block before DAB development (standard IHC practice). Evaluate each adjustment against preserved cytoplasmic signal in a positive control; stronger contrast alone does not establish specificity (HPA: cytoplasmic tissue expression; standard IHC practice).
How should I score ARHGEF2 staining across sections with different cell mixtures? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and compartment before scoring, because ARHGEF2 tissue staining is described as cytoplasmic and varies across cell types (HPA: cytoplasmic tissue expression). For each specimen, report the percentage of positive target cells and an intensity-weighted H-score from 0 to 300, using the same thresholds across slides (standard IHC practice). Where cell abundance itself matters, add positive-cell density per mm² of viable tissue and normalize staining to the number of eligible cells or analyzed viable area (standard IHC practice). Exclude necrosis, folds, and section edges using a prespecified rule, and score control sections alongside study sections to monitor run variation (standard IHC practice).
How do I distinguish genuine ARHGEF2 signal from staining artefacts?
Give greatest weight to reproducible cellular cytoplasmic staining, consistent with the reported tissue pattern and ARHGEF2 localization (HPA: cytoplasmic tissue expression; UniProt Q92974 subcellular). Check whether the positive cells match the population being evaluated: bone marrow hematopoietic cells and lymph-node germinal center cells are reported as High, whereas adipocytes are Not detected (HPA: tissue IHC). A uniform nuclear-only pattern, staining confined to cut edges or necrosis, or color in a no-primary control should prompt investigation of artefact or endogenous enzyme activity (standard IHC practice). Confirm a disputed pattern with adjacent sections, a peroxidase block, and an independent antibody or orthogonal measurement before making a biological claim (standard IHC practice).
Boster reagents
Best ARHGEF2 / Rho guanine nucleotide exchange factor 2 IHC Antibodies
Anti-ARHGEF2 A02572-3 has a human paraffin-section IHC image (catalog image caption); M02572-1 lists ICC/IF without an IF image (catalog applications and image alts). Both list Human, Mouse and Rat reactivity (catalog).
Real IHC data
Anti-GEF-H1/ARHGEF2 Antibody ®
Cat # A02572-3
A02572-3 is shown on human colon cancer and ovarian cancer paraffin sections (catalog IHC image captions). M02572-1 lists ICC/IF among its applications and Human, Mouse and Rat reactivity; no IF image is supplied (catalog applications, reactivity and image alts).
Which to pick: Choose A02572-3 for chromogenic tissue IHC: its human paraffin-section caption documents EDTA retrieval, an overnight primary incubation and HRP/DAB detection; the fixative is unreported (catalog IHC image caption). Choose rabbit monoclonal M02572-1 for IF/ICC because that application is listed with a 1:50 IF dilution, though no IF figure is supplied (catalog host, clone, applications, dilution and image alts). Both list Human, Mouse and Rat reactivity, but the supplied A02572-3 IHC images show human sections only (catalog reactivity and IHC image captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q92974 (ARHG2_HUMAN, Rho guanine nucleotide exchange factor 2).
- Human Protein Atlas. ARHGEF2 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. ARHGEF2 subcellular location (ICC-IF): Highest expression in THP-1: 180.9 nTPM.
- Human Protein Atlas. ARHGEF2 antibody validation summary (1 antibodies).
- Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer. Cell death & disease 2022 — PMC9637107.
- CCDC88B interacts with RASAL3 and ARHGEF2 and regulates dendritic cell function in neuroinflammation and colitis. Communications biology 2024 — PMC10781698.
- PubMed PMID:9857026 — UniProt-cited evidence.
- PubMed PMID:11912491 — UniProt-cited evidence.
- PubMed PMID:9734811 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for ARHGEF2 (Rho guanine nucleotide exchange factor 2). Expected localisation Variable cytoplasmic staining in tissues (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A02572-3). Validated IHC antibody: A02572-3 at 2-5 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Bone marrow (Hematopoietic cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human colon cancer tissue; fixative not specified (datasheet A02572-3); 2. Fixation: Image fixative and duration unreported (datasheet A02572-3); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A02572-3); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A02572-3); 8. Primary antibody: Rabbit anti-ARHGEF2, 2-5 μg/ml (datasheet A02572-3); 9. Primary incubation: Overnight at 4 °C (datasheet A02572-3). Watch for: Fixation: Keep fixation conditions consistent across sections. (standard IHC practice; not target-specific); Caveat: Staining has medium agreement with RNA expression (HPA tissue IHC); Isoform / epitope: 3 isoforms; epitope coverage is unknown (UniProt); Regulation: Stimulus-dependent expression is unreported (UniProt). Evidence: UniProt Q92974, HPA tissue IHC · Approved, HPA cell-line RNA · Highest expression in THP-1: 180.9 nTPM, Datasheet A02572-3, PMC9637107. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/ARHGEF2/immunohistochemistry-ihc-guide.